EP08.02-158 Final Analyses of ALTER-L018: A Randomized Phase II Trial of Anlotinib Plus Docetaxel Vs Docetaxel As 2Nd-Line Therapy for EGFR-negative NSCLC
Journal of Thoracic Oncology(2022)
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined